Summary
Updated Aug 31, 2026
Lawrence M. Alleva is Director of Galera Therapeutics, Inc. (GRTX). 3 SEC Form 4 filings on record going back to 2024, most recently on 5 August 2026.
Recent Transactions
3Every recent SEC Form 4 transaction Lawrence M. Alleva has reported, most recent first.
Trading Pattern
InsiderAlpha's records for Lawrence M. Alleva go back to 2024: 3 primary Form 4 filings, an average of 1.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Lawrence M. Alleva files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Mary Lou Burke - $356K of BFAM open-market activity in the last 12 months
- Mel Sorensen - $1K of GRTX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Lawrence M. Alleva?
Lawrence M. Alleva is a corporate insider, tracked as Director of Galera Therapeutics, Inc. (GRTX). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Lawrence M. Alleva submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of Lawrence M. Alleva's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Lawrence M. Alleva and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial